Page last updated: 2024-09-03

reboxetine and doxepin

reboxetine has been researched along with doxepin in 2 studies

Compound Research Comparison

Studies
(reboxetine)
Trials
(reboxetine)
Recent Studies (post-2010)
(reboxetine)
Studies
(doxepin)
Trials
(doxepin)
Recent Studies (post-2010) (doxepin)
626193184885207129

Protein Interaction Comparison

ProteinTaxonomyreboxetine (IC50)doxepin (IC50)
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)0.046
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)0.029
Muscarinic acetylcholine receptor M2Homo sapiens (human)0.258
Muscarinic acetylcholine receptor M4Homo sapiens (human)0.042
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)0.2
Muscarinic acetylcholine receptor M5Homo sapiens (human)0.026
Alpha-2A adrenergic receptorHomo sapiens (human)0.6675
Muscarinic acetylcholine receptor M1Homo sapiens (human)0.077
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)0.2
Alpha-2B adrenergic receptorHomo sapiens (human)0.0355
Alpha-2C adrenergic receptorHomo sapiens (human)0.5145
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)0.8595
Muscarinic acetylcholine receptor M3Homo sapiens (human)0.069
D(1A) dopamine receptorHomo sapiens (human)0.688
Sodium-dependent noradrenaline transporter Homo sapiens (human)0.029
Histamine H2 receptorHomo sapiens (human)1.867
Alpha-1D adrenergic receptorHomo sapiens (human)0.118
5-hydroxytryptamine receptor 2AHomo sapiens (human)0.038
5-hydroxytryptamine receptor 2CHomo sapiens (human)0.046
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)0.8595
5-hydroxytryptamine receptor 1DRattus norvegicus (Norway rat)0.2
5-hydroxytryptamine receptor 1FRattus norvegicus (Norway rat)0.2
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)0.2
5-hydroxytryptamine receptor 6Rattus norvegicus (Norway rat)0.2
Sodium-dependent serotonin transporterHomo sapiens (human)0.042
5-hydroxytryptamine receptor 7 Rattus norvegicus (Norway rat)0.2
5-hydroxytryptamine receptor 5ARattus norvegicus (Norway rat)0.2
5-hydroxytryptamine receptor 5BRattus norvegicus (Norway rat)0.2
Histamine H1 receptorHomo sapiens (human)0.0006
D(3) dopamine receptorHomo sapiens (human)1.393
5-hydroxytryptamine receptor 3ARattus norvegicus (Norway rat)0.2
5-hydroxytryptamine receptor 2BHomo sapiens (human)0.089
Histamine H2 receptorCavia porcellus (domestic guinea pig)1.6
5-hydroxytryptamine receptor 6Homo sapiens (human)0.32
5-hydroxytryptamine receptor 4 Rattus norvegicus (Norway rat)0.2
Sigma non-opioid intracellular receptor 1Homo sapiens (human)0.631
5-hydroxytryptamine receptor 3BRattus norvegicus (Norway rat)0.2

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bajbouj, M; Danker-Hopfe, H; Gallinat, J; Hellen, F; Lang, UE; Lisanby, SH; Neu, P; Vesper, J1
Jiao, Y; Liang, Y; Lin, J; Qu, H; Sun, Y; Xu, J; Zhao, C1

Trials

1 trial(s) available for reboxetine and doxepin

ArticleYear
Motor cortex excitability after vagus nerve stimulation in major depression.
    Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:2

    Topics: Adult; Benzodiazepines; Citalopram; Clomipramine; Clozapine; Depressive Disorder; Doxepin; Drug Therapy, Combination; Electric Stimulation; Female; Humans; Lamotrigine; Lithium Carbonate; Male; Mianserin; Middle Aged; Mirtazapine; Morpholines; Motor Cortex; Neural Conduction; Neural Inhibition; Olanzapine; Paroxetine; Psychiatric Status Rating Scales; Reboxetine; Tranylcypromine; Triazines; Vagus Nerve; Valproic Acid

2007

Other Studies

1 other study(ies) available for reboxetine and doxepin

ArticleYear
Comparative efficacy and acceptability of antidepressant treatment in poststroke depression: a multiple-treatments meta-analysis.
    BMJ open, 2017, Aug-03, Volume: 7, Issue:8

    Topics: Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depression; Depressive Disorder; Doxepin; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Morpholines; Paroxetine; Patient Acceptance of Health Care; Reboxetine; Selective Serotonin Reuptake Inhibitors; Stroke; Treatment Outcome

2017